Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
dc.contributor.author | Rosenke, K | |
dc.contributor.author | Hansen, F | |
dc.contributor.author | Schwarz, B | |
dc.contributor.author | Feldmann, F | |
dc.contributor.author | Haddock, E | |
dc.contributor.author | Rosenke, R | |
dc.contributor.author | Barbian, K | |
dc.contributor.author | Meade-White, K | |
dc.contributor.author | Okumura, A | |
dc.contributor.author | Leventhal, S | |
dc.contributor.author | Hawman, DW | |
dc.contributor.author | Ricotta, E | |
dc.contributor.author | Bosio, CM | |
dc.contributor.author | Martens, C | |
dc.contributor.author | Saturday, G | |
dc.contributor.author | Feldmann, H | |
dc.contributor.author | Jarvis, Michael A | |
dc.date.accessioned | 2021-08-09T12:36:20Z | |
dc.date.issued | 2021-04-16 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.other | 2295 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/17496 | |
dc.description.abstract |
<jats:title>Abstract</jats:title><jats:p>The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.</jats:p> | |
dc.format.extent | 2295- | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Nature Research (part of Springer Nature) | |
dc.subject | Administration, Oral | |
dc.subject | Animals | |
dc.subject | Antiviral Agents | |
dc.subject | COVID-19 | |
dc.subject | Chlorocebus aethiops | |
dc.subject | Cytidine | |
dc.subject | Disease Models, Animal | |
dc.subject | Humans | |
dc.subject | Hydroxylamines | |
dc.subject | Mesocricetus | |
dc.subject | SARS-CoV-2 | |
dc.subject | Vero Cells | |
dc.subject | Virus Replication | |
dc.subject | COVID-19 Drug Treatment | |
dc.title | Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Research Support, N.I.H., Intramural | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000641850500003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 1 | |
plymouth.volume | 12 | |
plymouth.publication-status | Published online | |
plymouth.journal | Nature Communications | |
dc.identifier.doi | 10.1038/s41467-021-22580-8 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Biomedical Sciences | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2021-02-18 | |
dc.rights.embargodate | 2021-8-14 | |
dc.identifier.eissn | 2041-1723 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1038/s41467-021-22580-8 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2021-04-16 | |
rioxxterms.type | Journal Article/Review |